Monika Zielińska-Pisklak

Dr. Monika Zielińska-Pisklak


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MSMariusz Sandomierski
Mariusz Sandomierski
MZMonika Zielińska-Pisklak
Monika Zielińska-Pisklak
Adam VoelkelAdam Voelkel
Adam Voelkel

1 March 2019 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
ZOZuzanna Okulus
Zuzanna Okulus
MSMariusz Sandomierski
Mariusz Sandomierski
MZMonika Zielińska-Pisklak
Monika Zielińska-Pisklak
Tomasz BuchwaldTomasz Buchwald
Tomasz Buchwald
Adam VoelkelAdam Voelkel
Adam Voelkel

21 July 2021 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
MSMariusz Sandomierski
Mariusz Sandomierski
MZMonika Zielińska-Pisklak
Monika Zielińska-Pisklak
Tomasz BuchwaldTomasz Buchwald
Tomasz Buchwald
Adam PatalasAdam Patalas
Adam Patalas
Adam VoelkelAdam Voelkel
Adam Voelkel

3 June 2021 in Materials Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
MSMariusz Sandomierski
Mariusz Sandomierski
MZMonika Zielińska-Pisklak
Monika Zielińska-Pisklak
AVAdam Voelkel
Adam Voelkel
The aim of this study was to prepare an implant material enabling a slow, gradual and gentle release of risedronate.

1 June 2021 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
MZMonika Zielińska-Pisklak
Monika Zielińska-Pisklak
ECEwa Chmielewska
Ewa Chmielewska
TBTomasz Buchwald
Tomasz Buchwald
AVAdam Voelkel
Adam Voelkel
PKPaweł Kafarski
Paweł Kafarski
There is a strong need to search for more effective compounds with bone anti-resorptive properties, which will cause fewer complications than commonly used bisphosphonates. To achieve this goal, it is necessary to search for new techniques to characterize the interactions between bone and drug. By studying their interaction with hydroxyapatite (HA), this study used three forms of ceramic materials, two of which are bone-stimulating materials, to assess the suitability of new active substances with anti-resorptive properties. In this study, three methods based on HA in loose form, polycaprolactone/HA (a polymer-ceramic materials containing HA), and polymer-ceramic monolithic in-needle extraction (MINE) device (a polymer inert skeleton), respectively, were used. The affinity of risedronate (a standard compound) and sixteen aminomethylenebisphosphonates (new compounds with potential antiresorptive properties) to HA was defined according to the above-mentioned methods. Ten monolithic materials based on 2-hydroxyethyl methacrylate/ethylene dimethacrylate are prepared and studied, of which one was selected for more-detailed further research. Simulated body fluids containing bisphosphonates were passed through the MINE device. In this way, sorption–desorption of bisphosphonates was evaluated using this MINE device. The paper presents the advantages and disadvantages of each technique and its suitability for assessing new active substances. All three methods allow for the selection of several compounds with potentially higher anti-resorptive properties than risedronate, in hope that it reflects their higher bone affinity and release ability.

15 July 2024 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
MZMonika Zielińska-Pisklak
Monika Zielińska-Pisklak
APAmanda Pacholak
Amanda Pacholak
NBNatalia Burlaga
Natalia Burlaga
ECEwa Chmielewska
Ewa Chmielewska
AVAdam Voelkel
Adam Voelkel
EKEwa Kaczorek
Ewa Kaczorek
Background: The study aimed to evaluate the therapeutic potential of fourteen newly synthesized bisphosphonates by assessing their bioavailability, bone affinity, and cytotoxicity. These bisphosphonates included a series of aminomethylenebisphosphonates and standard compounds such as risedronate and tiludronate. Methods: Drug permeability was determined using Parallel Artificial Membrane Permeability Assays (PAMPA), while bone affinity was assessed by sorption on hydroxyapatite. Bacterial cell response to the bisphosphonates was also examined using Lactobacillus paracasei cells as a model. Results: Several tested compounds, including BP3 to BP8 and BP11, which feature substituents in the pyridine ring such as methyl groups, iodine, bromine, chlorine, or hydroxyl groups, demonstrated potentially more beneficial therapeutic properties than commercially used bisphosphonates. These compounds showed stronger bone affinity and higher gastrointestinal absorption with comparable or lower cytotoxic effects. Specifically, BP11 exhibited the highest bone affinity, while BP8 and BP11 showed the greatest permeability. Conclusions: The findings suggest that BP3 BP8, and BP11 are promising candidates for further research. These results highlight the importance of comprehensively evaluating bisphosphonates' therapeutic properties to identify effective treatments for osteoporosis and other bone diseases. Graphical